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Recently, paclitaxel and then gemcitabine have emerged as prom-
ising new agents in first-line treatment of locally advanced and
metastatic non-small cell lung cancer (NSCLC). In several phase
II trials, single-agent paclitaxel has produced response rates of
21–38% and a 1-year survival rate of 35–42% (Chang et al, 1993;
Murphy et al, 1993; Alberola et al, 1995; Gatzemeier et al, 1995),
while response rates of 20–26% have been reported for single-
agent gemcitabine, with 1-year survival rates of 31–43%
(Anderson et al, 1994; Gatzemeier et al, 1996; Fukuoka et al,
1997; Yokoyama et al, 1997). 
Gemcitabine is a novel deoxycytidine analogue, which acts as a
competitive substrate for incorporation into DNA where it leads to
termination of DNA chain elongation (Plunkett et al, 1995). In
contrast, paclitaxel has no direct action on DNA synthesis, but acts
by promoting the polymerization of tubulin into stable micro-
tubules and inhibiting the formation of stable microtubule bundles,
ultimately leading to cell death (Schiff et al, 1979). Common
adverse events of gemcitabine are myelosuppression (mainly
neutropenia), hepatic abnormalities and nausea/vomiting (Noble
and Goa, 1997), while those commonly associated with paclitaxel
include neutropenia, anaemia, peripheral neuropathy, myalgia/
arthalgia, mucositis and alopecia (Wiseman and Spencer, 1998).
Based on their single-agent activity, different mechanisms of
action and essentially non-overlapping toxicities (Rowinsky and
Donehower 1995; Peters and Ackland, 1996), it seems important
to explore the potential of paclitaxel and gemcitabine in combina-
tion. This approach is supported by the lack of pharmacokinetic
interaction between the two drugs and the ability of paclitaxel 
to increase cellular accumulation of gemcitabine triphosphate
(dFdCTP), the active metabolite of gemcitabine, with the
possibility of enhancing its antitumor activity (Kroep et al, 1999).
Several phase I studies involving different schedules of paclitaxel
and gemcitabine in a variety of tumour types have been encour-
aging and mainly found neutropenia and elevated transaminase
levels to be dose-limiting (Poole et al, 1997; Sandler et al, 1997).
In a phase I/II dose-finding study in advanced NSCLC, gemcita-
bine 1000 mg/m2 was administered on days 1 and 8, and paclitaxel
150 to 200 mg/m2 as a 3-hour infusion on day 1 of a 21-day cycle
(Giaccone et al, 1998a). Preliminary data revealed that among the
first 30 patients enrolled, dose escalation was well tolerated and
the response rate was 30%; any failure to undergo dose escalation
was mainly unrelated to adverse effects. This schedule was also
investigated in a phase I/II study of the pharmacokinetic and phar-
macodynamic interactions between gemcitabine and paclitaxel in
patients with NSCLC (Kroep et al, 1999). Due to mild toxicity, the
dose of paclitaxel was increased from 150 to 200 mg/m2. 
Consequently, in view of the relatively mild toxicity profile, the
possibility of improved patient outcome, and the advantage of
dose administration on an out-patient basis, the present phase II
study was designed to investigate further the efficacy and safety
profile of combined paclitaxel and gemcitabine in advanced
NSCLC. 
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Summary The efficacy and toxicity of combined paclitaxel and gemcitabine was evaluated in 54 chemotherapy-naive patients with metastatic
non-small cell lung cancer (NSCLC). Gemcitabine i.v. 1000 mg/m2 was administered on days 1 and 8 and paclitaxel 200 mg/m2 as a
continuous 3-hour infusion on day 1. Treatment was repeated every 21 days. Patients had a median age of 53 years. ECOG performance
status was 0 or 1 in 48 patients. 41 patients (75.9%) had initial stage IV disease; histology was mainly adenocarcinoma (46.3%). 2 patients
(4.3%) achieved a complete response and 15 (31.9%) achieved a partial response giving an overall response rate of 36.2% (95% CI:
22.4–49.9%); 19 patients (40.4%) had stable disease and 10 (21.3%) had progressive disease. The median survival time was 51 weeks (95%
CI: 46.5–59.3), with a 1-year survival probability of 0.48 (95% CI: 0.34–0.63). Grade 3/4 neutropenia and febrile neutropenia occurred in
15.2% and 2.2% of courses, respectively. Grade 3/4 thrombocytopenia was rare (1.8% of courses). Peripheral neurotoxicity developed in 25
patients (47.2%), mostly grade 1/2. Arthalgia/myalgia was observed in 30 patients (56.6%), generally grade 1 or 2. Grade 3 abnormal levels
of serum glutamate pyruvate transaminase (SGPT) and serum glutamate oxaloacetate transaminase (SGOT) occurred in 5 patients (9.4%)
and 1 patient (1.9%), respectively. Combined paclitaxel and gemcitabine is an active and well-tolerated regimen for the treatment of advanced
NSCLC, and warrants further investigation in comparative, randomized trials. © 2001 Cancer Research Campaign http://www.bjcancer.com
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Patient population 
Chemotherapy-naive patients with histologically or cytologically
confirmed stage IV (Mountain, 1997) or relapsed metastatic
NSCLC after surgery and/or radiotherapy were included in the
study. Further inclusion criteria were: age between 18 and 75
years; Eastern Cooperative Oncology Group (ECOG) performance
status ≤ 2 (Minna et al, 1984); life expectancy ³12weeks; at least
one bidimensionally measurable lesion (2 cm ´ 2 cm minimum)
located outside previously irradiated locations; and adequate
haematological (absolute neutrophil count [ANC] ³1500 ml–1,
platelet count ³100 000 ml)–1, renal (serum creatinine ≤1.5 ´ upper
normal limit), and hepatic (bilirubin ≤1.5 ´ upper normal limit,
serum glutamate oxaloacetate transaminase (SGOT) and serum
glutamate pyruvate transaminase (SGPT) ≤2.5  ´  upper normal
limit) functions. Patients were excluded if they had brain metas-
tasis, a history of neoplasm (except cured non-melanoma skin
carcinoma or carcinoma in-situ of the cervix), history of cardiac
disease (uncontrolled hypertension, unstable angina, congestive
heart failure, second- or third-degree heart block, myocardial
infarction within the previous year, cardiac ventricular arrhyth-
mias requiring medication), peripheral neuropathy, a psychiatric
disorder, serious active infection, or allergic reaction to 
preparations containing cremophor. Females of childbearing
potential had to have a negative serum or urine pregnancy test
within 48 hours of enrolment and had to use adequate contracep-
tive measures during the study. Pregnant or lactating women were
excluded. Patients with previous radiotherapy were included
providing treatment was completed 4 weeks before starting treat-
ment and they had recovered from all adverse effects, and less than
30% of marrow-bearing bones were irradiated. Also, major
surgery must have been completed at least 2 weeks before enrol-
ment. Approval of the study (including the informed consent form)
was given by the Consultative Committee for the Protection of
Persons involved in Biomedical Research of Nantes, and all
patients gave written informed consent. 
Patient evaluation 
Pretreatment evaluation included a physical examination, electro-
cardiogram (ECG), and laboratory tests (haematology and
biochemistry). Tumour sites were assessed by physical examina-
tion and computed tomography (CT) scans of the thorax, abdomen
and brain. An isotopic bone scan or X-ray was taken to detect bone
metastases and assess as much as possible the disease extension, a
known prognostic factor. During treatment, a physical examina-
tion, a pregnancy test (if applicable), an ECG, and haematology
and biochemistry assessments preceded each treatment course.
Before the second dose of gemcitabine on every treatment course
(day 8), patients had an ECG and haematology tests (haemoglobin,
white blood cells, ANC and platelets count). 
Tumour sites were evaluated by physical examination every
cycle and by CT imaging every 2 cycles. Adverse events were
evaluated according to The National Cancer Institute Common
Toxicity Criteria (NCI-CTC) scale. On study completion or
discontinuation, follow-up of disease status, survival and tolerance
was performed every 3 months until disease progression. After
progression, follow-up for survival continued every 3 months for
the first 2 years and then every 6 months. 
Treatment schedule 
Gemcitabine (Gemzar®; Eli-Lilly, Indianapolis, IN) 1000 mg/m2
was administered as a 30 minute intravenous infusion on day 1 and
day 8. On day 1 gemcitabine was given before paclitaxel (Taxol®;
Bristol-Myers Squibb, Mayaguez, Puerto Rico) 200 mg/m2 diluted
in 500 ml of 5% dextrose (final concentration was not to exceed
1.2 mg ml)–1 administered as a 3 hour infusion. Premedication to
prevent possible anaphylactic reaction comprised intravenous
dexamethasone 20 mg, dexchlorpheniramine 5 mg, and cimetidine
300 mg or ranitidine 50 mg, all given 30 minutes before paclitaxel.
Courses were repeated every 21 days or upon haematologic
recovery (ANC ³1500 ml–1 and platelet count ³100 000 ml)–1. If
haematologic recovery was not achieved by day 35, treatment was
discontinued. Gemcitabine administration on day 8 could be
delayed to day 15 according to haematologic recovery (ANC 
³ 1000 ml–1 and platelet count ³100 000 ml–1). 
Dose reductions to paclitaxel 175 mg/m2 and gemcitabine 750
mg/m2 were made in case of haematologic toxicity (ANC <500 ml–1
for ³7 days, febrile neutropenia, grade 4 thrombocytopenia, grade 4
anaemia, bleeding episode requiring platelet transfusion) and
nonhaematologic toxicity (mucositis with ulcers WHO grade ³3).
Doses were reduced to paclitaxel 150 mg/m2 and gemcitabine 500
mg/m2 for elevated bilirubin levels grade 3. Dose reductions in
paclitaxel alone to 175 mg/m2 were made for severe myalgia/
arthralgia or peripheral neurotoxicity grade 2 (a further reduction to
paclitaxel 150 mg/m2 was made if peripheral neurotoxicity grade 2
persisted). Dose re-escalation was not allowed. Treatment was
discontinued in case of severe myalgia/arthralgia lasting ³7 days,
hepatotoxicity (bilirubin grade 4, persistent elevated transaminases
grade 3 or 4), peripheral neurotoxicity grade 3, symptomatic
arrhythmia or heart block (except first degree AV block), or other
major organ toxicity grade 3 or 4 (except alopecia or vomiting) not
recovered after dose reduction or a 2-week delay. Other anticancer
drugs, immunotherapy and radiotherapy were prohibited. Treat-
ment was continued in the absence of disease progression and
unacceptable toxicity for a maximum of 10 courses.
Criteria for response 
Response to treatment was assessed every two courses according
to World Health Organization (WHO) response criteria (Miller 
et al, 1981). Complete response (CR) required disappearance of all
clinical evidence of tumour, determined by 2 observations at least
4 weeks apart. Partial response (PR) required 50% or more reduc-
tion in the sum of the products of the perpendicular dimensions of
measured lesions, determined by 2 observations at least 4 weeks
apart without the appearance of new lesions. Stable disease (SD)
was defined as a decrease in lesion size of less than 50% in the
sum of the products of measured lesions or progression less than
25% for a minimum of 4 weeks, without the appearance of new
lesions. Progressive disease (PD) was defined as an increase in
lesion size of at least 25% or the appearance of new lesions. Bone
disease was evaluated separately in the reporting of CR and
patients with bone metastases were included in the reporting of
overall response (CR and PR) according to a separate set of
response criteria (CR was complete disappearance of all lesions on
X-ray or scan for at least 4 weeks, without the appearance of new
lesions; PR was at least a 50% decrease in the size of lytic lesions,
or decreased density of blastic lesions for at least 4 weeks); SD
was not applied until at least 8 weeks after the start of therapy
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in size of existing lesions or appearance of new lesions. 
Statistics 
All patients who received at least 2 courses of treatment were eval-
uable for response. In case of progression following the first
course, patients were evaluated as ‘early progression’. Patients
who received at least one course of treatment were assessable for
toxicity. The study used a 2-stage Simon optimum design (Simon,
1989), where a population response rate of less than 15% is
considered insufficiently effective and one of 35% or more is
considered worthy of further investigation. In the first stage of the
study, 19 patients evaluable for response were considered and if 4
or more patients showed a partial or complete response, a further
25 response-evaluable patients were enrolled. If 11 of 44 patients
responded, the treatment regimen was considered a useful combi-
nation for phase III studies. This procedure has a power of 90% to
detect a true response rate of 35%, at a confidence level of 5%. A
two-sided exact 95% confidence test was performed on the
response rate (ratio between the number of patients with complete
or partial response and the total number of patients studied). The
Kaplan–Meier method (Kaplan and Meier, 1958) was used to
calculate time to response (time from enrolment to complete or
partial response), response duration (time from partial or complete
response to disease progression), progression-free survival (time
from enrolment to disease progression), and overall survival 
(time from enrolment to death). 
RESULTS 
Patient characteristics 
A total of 54 patients (49 men and 5 women), with a median age of
53 years (range, 37–74 years) were enrolled in the study. Most
patients had a performance status of 0–1 (88.9%; one patient had a
performance status of 3 that exceeded the inclusion criteria, this
patient was excluded from the efficacy and safety evaluation),
initial stage IV disease (75.9%), and adenocarcinoma (46.3%)
(Table 1). 53 patients were assessable for toxicity, and 47 fulfilled
all criteria for response evaluation. 
Compliance with treatment 
A total of 276 courses were administered to 53 patients, with a
median of 6 courses per patient (range, 1–10) and the median
interval between courses was 21 days (range, 20–35 days). Mean
dose intensities for paclitaxel and gemcitabine were 65 mg/m2/
week (97.6%) and 659 mg/m2/week (94.3%) respectively. 30
patients (56.6%) received 6 or more courses and 3 (5.7%) received
all 10 courses. Treatment was delayed in 23 courses (8.3%), for
haematologic complications in 5 courses (3 patients, 5.7%) and
nonhaematologic complications in 2 courses (1 patient, 1.9%), and
other reasons, mainly non-medical, in 16 courses (14 patients,
26.4%). The scheduled dose of gemcitabine on day 8 was omitted
completely in 5 courses (5 patients, 9.4%) due to left ventricular
decompensation, dyspnoea and pneumothorax, and haematologic
toxicity in one course, and disease progression in two courses.
Three, day-8 doses of gemcitabine were delayed until day 15 in
one patient, because of haematologic toxicity in two courses and
by error in one course. One infusion of paclitaxel was temporarily
interrupted by a hypersensitivity reaction. Paclitaxel dose reduc-
tions were required in 7 courses (7 patients, 13.2%) due to nonhae-
matologic toxicity (peripheral neurotoxicity in 4, arthromyalgia in
3). No dose reduction was required for gemcitabine alone. Both
paclitaxel and gemcitabine doses were reduced in 3 courses due to
haematologic toxicity in 2 (thrombocytopenia grade 4 and febrile
neutropenia grade 4) and nonhaematologic toxicity in 1 (transient
increase in SGPT and SGOT). 
Toxicity 
The major haematologic and nonhaematologic toxicities asso-
ciated with this regimen are shown in Tables 2 and 3. Grade 3 and
4 neutropenia occurred in 15.2% of treatment courses, and febrile
neutropenia was observed in 2.2% of courses. Episodes of grade 3
and 4 thrombocytopenia were infrequent, occurring in 1.8% of
Paclitaxel-gemcitabine in metastatic NSCLC 1181
British Journal of Cancer (2001) 84(9), 1179–1184 © 2001 Cancer Research Campaign
Table 1 Patient characteristics 
Patients 
Number % 
Total 54
Sex 
Male 49 90.7% 
Female 5 9.3% 
Age (years) 
Median 53 
Range 37–74 
ECOG performance status 
0 15 27.8 
1 33 61.1 
2 5 9.3 
3 1 1.9 
Histology 
Adenocarcinoma 25 46.3 
Squamous cell carcinoma 15 27.8 
Large-cell carcinoma 10 18.5 
Other 4 7.4 
Stage 
IIIB (lymphangitis or pleural effusion) 5  9.3 
IV 41 75.9 
Metastatic relapse 8 14.8 
Metastatic sites:  bone 14 
adrenal 10 
liver 14 
lung 5 
brain 1 
kidney 2 
abdominal nodes 10 
Prior therapy 
Radiotherapy 13 24.1 
Surgical resection 9 16.7 
Table 2 Haematologic toxicity, in all treatment courses (n = 276) 
Number of treatment courses (%) 
Toxicity NCI-CTCa grade 
1234  
Neutropenia 30 (10.9) 13 (4.7) 29 (10.5)  13 (4.7) 
Thrombocytopenia – 4 (1.4) 3 (1.1)  2 (0.7) 
Anaemia – 47 (17.0) 6 (2.2) – 
Infection 1 (0.4) 1 (0.4) – – 
aThe National Cancer Institute Common Toxicity Criteria. courses and were not complicated by haemorrhage. No grade 4
anaemia was observed. Nonhaematologic toxic effects were gener-
ally mild to moderate. Peripheral neurotoxicity was reported in 25
patients (47.2%), mostly grade 1 and 2 and symptoms were not
more severe or more prolonged than may have been expected from
paclitaxel alone. Arthalgia/myalgia was observed in 30 patients
(56.6%), but episodes were generally grade 1 or 2. Grade 3
nausea/vomiting was reported in 2 patients (3.8%); no grade 4
toxicity occurred. Nephrotoxicity (abnormal levels of serum crea-
tinine) did not exceed grade 1. Hepatotoxicity was mainly mild;
grade 2 abnormal levels of total bilirubin were observed in 52
patients (98.1%). Grade 3 abnormal levels of SGPT and SGOT
occurred in 5 patients (9.4%) and 1 patient (1.9%), respectively;
no grade 4 levels were reported. Hypersensitivity reactions were
observed in 5 patients (9.4%). Cardiotoxicity was reported in 4
patients (7.5%) as pericardial effusion and atrial flutter (1 patient),
and either left ventricular failure, parasympatic malaise or thoracic
pain (1 patient each). 7 patients (13.2%) discontinued treatment
due to toxic effects (paraesthesia in 2; hepatotoxicity in 3; 1 each
for myalgia grade 3 and cardiac failure). 
Response and survival 
Among 47 assessable patients, 2 patients (4.3%) achieved a CR
and 15 patients (31.9%) achieved a PR, giving an overall response
rate of 36.2% (95% CI: 22.4–49.9%). 5 out of 15 patients who
achieved PR had initial bone metastasis. 19 patients (40.4%) had
stable disease and 10 (21.3%) had progressive disease.
Determination of response was not possible in one patient (2.1%).
The overall response rate was 32.1% (95% CI: 19.5–44.6%) for
the population who received at least one course of treatment. The
median time to response was 11.5 weeks (95% CI: 6–12). The
median duration of response was 22.5 weeks (95% CI: 19–29) and
the median duration of progression-free survival was 25 weeks
(95% CI: 18–31.3). The median survival time was 51 weeks (95%
CI: 46.5–59.3), with a 1-year survival probability of 0.48 (95% CI:
0.34–0.63) (Figure 1). Response was achieved in all histologic
types, squamous cell (5 of 11 evaluable patients, 45.5%), adeno-
carcinoma (8 of 23 evaluable patients, 34.8%) and large cell carci-
noma (2 of 9 evaluable patients, 22.2%). 
DISCUSSION 
Platinum-based combination chemotherapy has played a pivotal
role in the treatment of advanced NSCLC. Examples of effective
combinations include gemcitabine plus cisplatin (response rates of
30–54% and median survivals of 13–66 weeks (Abratt et al, 1997;
Crino et al, 1997; Sandler et al, 2000)), paclitaxel plus cisplatin 
(response rates of 41–47% and an estimated median survival of 43
weeks (Klastersky and Sculier, 1995; Pirker et al, 1995; Giaccone
et al, 1998b)), paclitaxel plus carboplatin (response rates from
27% to 62%, a median survival of 34.3–56.7 weeks and a 1-year
survival of 32–54% depending on the dosing schedule of pacli-
taxel (Langer et al, 1995; Johnson et al, 1996; Hainsworth et al,
1998)), and navelbine plus cisplatin (a response rate of 43% and a
median survival of 35.3 weeks (Depierre et al, 1994)). 
However, the emergence of new agents with superior single-
agent activity to cisplatin and carboplatin has presented an 
opportunity to investigate the efficacy and safety of non-platinum-
containing combinations in this clinical setting (Lilenbaum and
Green, 1993). Exploration of combined paclitaxel and gemcitabine
in advanced NSCLC is particularly promising because of their
confirmed activity as single-agents and predominantly nonover-
lapping toxicities. The results of the present study (overall 
objective response rate of 36.2%, a median survival of 51 weeks,
and a 1-year survival of 48%) indicate that combined paclitaxel
and gemcitabine provides similar anticancer activity as the new
platinum-based regimens for the first-line treatment of advanced
NSCLC. Similar results (response rate of 37.5%, a median
survival of 55.7 weeks and an actuarial 1-year survival of 50.7%)
have been obtained in a recent phase II study of gemcitabine
combined with docetaxel, another taxane (Georgoulias et al, 1999).
The most encouraging aspect of the present study was the
acceptable safety profile obtained without the use of haemato-
poietic growth factors. Although grade 3 or 4 neutropenia occurred
in 15.2% of cycles, febrile neutropenia developed in only 2.2% of
courses and was easily managed. Episodes of grade 3 and 4 throm-
bocytopenia were infrequent, occurring in 1.8% of courses, but
were not complicated by haemorrhage. There were no grade 
4 nonhaematologic toxicities; peripheral neurotoxicity and
arthralgia/myalgia (which occurred in 47.2% and 56.6% of
patients, respectively) were mainly grade 1 or 2. The safety profile
of paclitaxel-gemcitabine in the present study was clearly distin-
guishable from the safety profiles of 4 platinum-containing
regimen reported in a recent randomized phase III trial (Schiller 
et al, 2000). Grade 4 neutropenia and Grade 3–4 febrile neutropenia
occurred in 55%, 37%, 49% and 42%, and 16%, 4% 10% and 3%
of patients in the gemcitabine-cisplatin, docetaxel-cisplatin, pacli-
taxel-carboplatin and paclitaxel-cisplatin groups, respectively. 
Triplet regimens of paclitaxel and gemcitabine in combination
with platinum compounds (cisplatin or carboplatin) have also been
evaluated. At various dosing schedules, the response rates have
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Table 3 Nonhaematologic toxicity, in 53 assessable patients 
Number of patients (%) 
Toxicity NCI-CTCa grade 
123 4  
Neurotoxicity 10 (18.9) 13 (24.5) 2 (3.8) – 
Stomatitis 6 (11.3) 1 (1.9) 1 (1.9) – 
Myalgia/arthralgia 12 (22.6) 14 (26.4) 4 (7.5) – 
Nausea/vomiting 14 (26.4) 13 (24.5) 2 (3.8)  – 
Alopecia 5 (9.4) 43 (81.1) – – 
Hypersensitivity reactions 3 (5.7) 1 (1.9) 1 (1.9) – 
aThe National Cancer Institute Common Toxicity Criteria. 
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Figure 1 Overall survival of patients with advanced NSCLC treated with
combined paclitaxel and gemcitabine. The 1-year survival probability is 0.48
(95% CI: 0.34–0.63)ranged from 44% to 57% with 1-year survival rates of 42% to 45%
(Frasci et al, 1999; Hainsworth et al, 1999; Sørensen et al, 1999)
Myelosuppression was the commonest toxicity. From these
studies, it is apparent that despite improvements in response, there
was no survival advantage and the significant myelotoxicity
suggests that paclitaxel/gemcitabine/cisplatin or carboplatin
combinations may be more appropriate for patients with good
performance status, possibly in a neoadjuvant setting. 
In view of the favourable safety profile of combined paclitaxel
and gemcitabine, coupled with encouraging response and survival
rates, further comparative randomized trials are justified to analyse
the quality-of-life and cost-effectiveness of this highly effective
combination, in addition to defining any safety advantages over
platinum-based regimens in advanced NSCLC. 
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